Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-161.31M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.58 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -81.47% |
| Return on Assets (Trailing 12 Months) | -66.70% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.11 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.85 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.80 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.64 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.65 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.53M |
| Free Float | -- |
| Market Capitalization | $601.07M |
| Average Volume (Last 20 Days) | 0.65M |
| Beta (Past 60 Months) | 2.62 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 18.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |